Recombinant Human CX3CL1/Fractalkine (FKN)

Fractalkine (FKN) is a transmembrane mucin-chemokine hybrid molecule expressed on activated endothelium1 that mediates attachment and firm adhesion of T cells, monocytes and NK cells.2 FKN plays an important proinflammatory role in rheumatoid arthritis (RA) pathogenesis as characterized by induction of synovial angiogenesis, chemotaxis, activation of monocytes and T cells as well as the stimulation of proliferation and synthesis of matrix degrading enzymes (matrix metalloproteinases, MMP) in synovial fibroblasts. Fractalkine thus may represent a novel target molecule for therapeutic intervention in RA.3 FKN is also an essential biomarker for predicting the prognosis of patients with colorectal cancer (CRC).4

This recombinant protein was lyophilized from a 0.2 μm filtered solution in 35% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid (TFA).

This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution, this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.